Clinical trial Recruiting at 2 sites Interventional Ages 18 and up Women only

Using indocyanine green to find sentinel lymph nodes during mastectomy

Official title: Indocyanine Green Guided Identification of Sentinel Lymph Nodes Via Mastectomy Incision in Breast Cancer Patients (INIGMA Study)

Run by St. Antonius Hospital · NCT07362485 · Data updated 2026-11-12

This pilot will test whether injecting indocyanine green and using fluorescence during mastectomy can find sentinel lymph nodes in women with clinically node-negative invasive breast cancer.

Quick facts

Study typeInterventional
Ages18 Years and up
SexWomen only
Enrollment90 (estimated)
SponsorSt. Antonius Hospital
Academic / other
Locations2 sites (Zwolle, Overijssel and 1 other locations)
StatusRecruiting
StartedAugust 22, 2022
Main results expectedApril 2026
Study endsJune 2026
Registry record updatedJanuary 23, 2026
Trial IDNCT07362485 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Women with biopsy-proven, clinically node-negative invasive T1–T3 breast cancer who are scheduled for mastectomy with a sentinel node procedure and can give informed consent are eligible.

Probably not a fit

Patients planning breast-conserving surgery, immediate reconstruction, with known allergy to ICG or technetium, with other concurrent solid tumors, or with clinically node-positive disease are unlikely to benefit from this approach.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter pilot enrolls women with clinically node-negative, invasive T1–T3 breast cancer who are having a mastectomy with a sentinel lymph node procedure at St. Antonius or Isala Hospital. All participants receive the standard preoperative 99mTc injection, then 5 mg of indocyanine green (ICG) after anesthesia, and surgeons search for fluorescent sentinel nodes through the mastectomy incision without making a separate axillary cut. The primary outcome is the ICG detection rate of sentinel lymph nodes via the mastectomy incision. Secondary outcomes compare ICG with 99mTc detection, number and concordance of nodes found, pathology differences, detection time, and complications.

Why it matters

Potential benefit: If successful, the technique could allow surgeons to locate sentinel nodes through the mastectomy incision without an extra axillary incision, potentially reducing additional incisions and operative burden.

How similar studies have gone: ICG-fluorescence for SLNB via a dedicated axillary incision has shown good diagnostic performance in prior work and is used clinically, but using only the mastectomy incision for ICG-guided detection is novel and not well described.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Clinically node-negative, DCIS, invasive T1- T3 breast cancer confirmed by biopsy.
* Preoperative axillary ultrasound to confirm clinical node-negative status.
* Indication (or preference) for mastectomy and simultaneous SLN procedure.
* Written informed consent according to ICH/GCP and national regulations.

Exclusion Criteria:

* Patients \< 18 years old
* Breast conserving surgery
* Direct reconstruction (with autologous tissue or implant)
* Known allergy for indocyanine green (ICG) or radioisotope technetium (99mTc), intravenous contrast or iodine
* Other concurrent solid tumour
* Hyperthyroidism or thyroid cancer
* Pregnancy or breast feeding
* Psychological, familial, sociological or geographical factors that could potentially hamper compliance with the study protocol

Where it's running

  • Isala
    Zwolle, Overijssel, Netherlands
    Recruiting
  • St. Antonius Ziekenhuis
    Utrecht, Utrecht, Netherlands
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.